Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Sutro Biopharma (STRO) EBIT Margin (2017 - 2025)

Historic EBIT Margin for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to 499.94%.

  • Sutro Biopharma's EBIT Margin rose 2972300.0% to 499.94% in Q3 2025 from the same period last year, while for Sep 2025 it was 197.53%, marking a year-over-year decrease of 1125600.0%. This contributed to the annual value of 384.34% for FY2024, which is 3262600.0% down from last year.
  • As of Q3 2025, Sutro Biopharma's EBIT Margin stood at 499.94%, which was up 2972300.0% from 5.25% recorded in Q2 2025.
  • In the past 5 years, Sutro Biopharma's EBIT Margin ranged from a high of 37.95% in Q4 2023 and a low of 1202.0% during Q1 2025
  • In the last 5 years, Sutro Biopharma's EBIT Margin had a median value of 333.26% in 2023 and averaged 365.27%.
  • Per our database at Business Quant, Sutro Biopharma's EBIT Margin skyrocketed by 6081700bps in 2023 and then crashed by -7669500bps in 2025.
  • Over the past 5 years, Sutro Biopharma's EBIT Margin (Quarter) stood at 328.85% in 2021, then tumbled by -73bps to 570.23% in 2022, then surged by 107bps to 37.95% in 2023, then crashed by -1261bps to 440.66% in 2024, then fell by -13bps to 499.94% in 2025.
  • Its EBIT Margin stands at 499.94% for Q3 2025, versus 5.25% for Q2 2025 and 1202.0% for Q1 2025.